NeurologyLive® Friday 5 — July 14, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Episode 93: Caring for Women With Parkinson Disease

In episode 93 of the Mind Moments Podcast, Jill Farmer, DO, MPH, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more.

2: MEDCast: Pregnancy and Family Planning Considerations When Treating Patients With Multiple Sclerosis

In this episode of MEDcast, Dr Krieger, Dr Brandstadter, and Dr Bove discuss MS care in patients who are considering pregnancy. They highlight treatment options, monitoring recommendations during and after pregnancy, as well as other crucial considerations when caring for patients with childbearing goals.

3: NeuroVoices: Crystal Proud, MD, on Improving SMA Outcomes Through a Combination Approach

In the latest edition of our in-depth Q&A series, the director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, provided perspective on the phase 4 RESPOND study assessing nusinersen in individuals with SMA who already received gene therapy.

4: Efforts Needed to Reach Underserved Communities, Advance Pain Medicine Research: Burel Goodin, PhD

The professor of anesthesiology at Washington University in St. Louis discussed the reasons behind his presentation at the 2023 AHS Annual Meeting on engaging underserved populations in pain medicine research. [WATCH TIME: 3 minutes]

5: Lecanemab’s Impact on Care and Diagnosis and the Future of Alzheimer Disease Treatment

Howard Fillit, MD, the cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation, shared his reactions to the recent approval of lecanemab and how it opens doors for future drug development in Alzheimer disease.